You are here: Industry Insights > Secura Bio

News List

Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma And Voluntary U.S. Withdrawal Of The Relapsed Or Refractory Follicular Lymphoma Indication Drugs
December 08, 2021
Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies...
Verastem to divest Copiktra rights to Secura Bio for up to $381m pharmaceutical-technology
August 12, 2020
Biopharmaceutical company Verastem has signed a definitive agreement to divest the global commercial and development rights for Copiktra (duvelisib) to Secura Bio in a deal valued at up to $381m.
Secura Bio Acquires Global Rights To Farydak® pharmafocusasia
March 13, 2019
Secura Bio, Inc., an integrated, commercial-stage biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies, today announced that it has acquired the global rights to Farydak® (panobinostat) from Novartis.